CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 25 enrolled
Drug / intervention
Octanormbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03988426
NCT03988426Phase 3Completed
CompareCT.gov

Clinical Phase 3 Study to Evaluate the Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Primary Immunodeficiency Diseases.

Octapharma·interventional·Posted Jun 17, 2019·Updated Mar 10, 2020

In Brief

A Phase 3 clinical trial evaluating Octanorm for Primary Immune Deficiency Disorder. Completed, enrolled 25 participants across 5 sites.

Detailed Summary

Clinical phase 3 study to evaluate the efficacy, tolerability and safety of subcutaneous human immunoglobulin (octanorm) in patients with primary immunodeficiency diseases.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Immune Deficiency Disorder
CountriesRussia
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 17, 2019
Enrollment StartMar 7, 2017
Primary CompletionJan 26, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.0 years ago

Interventions

Octanormbiological

Octanorm